Terms: = Brain cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Staging
13 results:
1. Prognostic nomograms for breast cancer with lung metastasis: a SEER-based population study.
Xie Y; Lei C; Ma Y; Li Y; Yang M; Zhang Y; Law KN; Wang N; Qu S
BMC Womens Health; 2024 Jan; 24(1):16. PubMed ID: 38172874
[TBL] [Abstract] [Full Text] [Related]
2. Overall survival and associated factors in women with metastatic breast cancer treated with trastuzumab at a public referral institution.
Gonçalves DS; Santos AMRD; Costa SCVD; Costa RSD; Senna KMSE; Zimmermann IR
Rev Bras Epidemiol; 2023; 26():e230045. PubMed ID: 37878833
[TBL] [Abstract] [Full Text] [Related]
3. brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced her2 + breast cancer.
Noteware L; Broadwater G; Dalal N; Alder L; Herndon Ii JE; Floyd S; Giles W; Van Swearingen AED; Anders CK; Sammons S
Breast Cancer Res Treat; 2023 Jan; 197(2):425-434. PubMed ID: 36403183
[TBL] [Abstract] [Full Text] [Related]
4. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
5. Clinical features of patients with her2-positive breast cancer and development of a nomogram for predicting survival.
Fan Y; Wang Y; He L; Imani S; Wen Q
ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of
Shahsavari S; Shaghaghi Z; Abedi SM; Hosseinimehr SJ
Int J Radiat Biol; 2020 Apr; 96(4):502-509. PubMed ID: 31829777
[No Abstract] [Full Text] [Related]
7. Overuse of Preoperative staging of Patients Undergoing Neoadjuvant Chemotherapy for Breast cancer.
Srour MK; Lee M; Walcott-Sapp S; Luu M; Chung A; Giuliano AE; Amersi F
Ann Surg Oncol; 2019 Oct; 26(10):3289-3294. PubMed ID: 31342365
[TBL] [Abstract] [Full Text] [Related]
8. Complete pathologic response of her2-positive breast cancer liver metastasis with dual anti-her2 antagonism.
Schoellhammer HF; Hsu F; Vito C; Chu P; Park J; Waisman J; Kim J
BMC Cancer; 2014 Apr; 14():242. PubMed ID: 24708527
[TBL] [Abstract] [Full Text] [Related]
9. Cranial magnetic resonance imaging in the staging of her2-positive Breast cancer Patients.
Kaplan MA; Inal A; Kucukoner M; Urakci Z; Ekici F; Firat U; Zincircioglu SB; Isikdogan A
Onkologie; 2013; 36(4):176-81. PubMed ID: 23548965
[TBL] [Abstract] [Full Text] [Related]
10. Leptomeningeal metastasis.
Chamberlain MC
Semin Neurol; 2010 Jul; 30(3):236-44. PubMed ID: 20577930
[TBL] [Abstract] [Full Text] [Related]
11. Metastatic breast cancer with her2/neu-positive cells tends to have a morbid prognosis.
Emi Y; Kitamura K; Shikada Y; Kakeji Y; Takahashi I; Tsutsui S
Surgery; 2002 Jan; 131(1 Suppl):S217-21. PubMed ID: 11821814
[TBL] [Abstract] [Full Text] [Related]
12. Predicting the sites of metastases from lung cancer using molecular biologic markers.
D'Amico TA; Aloia TA; Moore MB; Conlon DH; Herndon JE; Kinch MS; Harpole DH
Ann Thorac Surg; 2001 Oct; 72(4):1144-8. PubMed ID: 11603427
[TBL] [Abstract] [Full Text] [Related]
13. Clinical and molecular stratification of disease risk in medulloblastoma.
Gilbertson R; Wickramasinghe C; Hernan R; Balaji V; Hunt D; Jones-Wallace D; Crolla J; Perry R; Lunec J; Pearson A; Ellison D
Br J Cancer; 2001 Sep; 85(5):705-12. PubMed ID: 11531256
[TBL] [Abstract] [Full Text] [Related]